GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ReNeuron Group PLC (FRA:RQE1) » Definitions » EV-to-Revenue

ReNeuron Group (FRA:RQE1) EV-to-Revenue : -11.51 (As of May. 24, 2024)


View and export this data going back to 2007. Start your Free Trial

What is ReNeuron Group EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, ReNeuron Group's enterprise value is €-3.29 Mil. ReNeuron Group's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 was €0.29 Mil. Therefore, ReNeuron Group's EV-to-Revenue for today is -11.51.

The historical rank and industry rank for ReNeuron Group's EV-to-Revenue or its related term are showing as below:

FRA:RQE1' s EV-to-Revenue Range Over the Past 10 Years
Min: -561.86   Med: 88.11   Max: 3165.04
Current: -11.33

During the past 13 years, the highest EV-to-Revenue of ReNeuron Group was 3165.04. The lowest was -561.86. And the median was 88.11.

FRA:RQE1's EV-to-Revenue is ranked better than
97.5% of 1038 companies
in the Biotechnology industry
Industry Median: 8.22 vs FRA:RQE1: -11.33

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-24), ReNeuron Group's stock price is €0.034. ReNeuron Group's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was €0.01. Therefore, ReNeuron Group's PS Ratio for today is 6.80.


ReNeuron Group EV-to-Revenue Historical Data

The historical data trend for ReNeuron Group's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ReNeuron Group EV-to-Revenue Chart

ReNeuron Group Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 144.01 3.26 178.56 8.48 -2.94

ReNeuron Group Semi-Annual Data
Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 8.48 - -2.94 -

Competitive Comparison of ReNeuron Group's EV-to-Revenue

For the Biotechnology subindustry, ReNeuron Group's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ReNeuron Group's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ReNeuron Group's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where ReNeuron Group's EV-to-Revenue falls into.



ReNeuron Group EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

ReNeuron Group's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=-3.291/0.286
=-11.51

ReNeuron Group's current Enterprise Value is €-3.29 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ReNeuron Group's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 was €0.29 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ReNeuron Group  (FRA:RQE1) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

ReNeuron Group's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.034/0.005
=6.80

ReNeuron Group's share price for today is €0.034.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Sep. 2023 was €0.01.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ReNeuron Group EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of ReNeuron Group's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


ReNeuron Group (FRA:RQE1) Business Description

Traded in Other Exchanges
Address
Pencoed Business Park, Pencoed, Bridgend, GBR, CF35 5HY
ReNeuron Group PLC is engaged in the field of biotechnology. Its core activities include the research and clinical development of cell-based therapeutics. The company product pipeline includes the human retinal progenitor cell line (hRPC) and CTX neural cell line. It derives revenue from UK and U.S. The company is mainly focusing on the treatment of stroke disability, inherited retinal diseases, and cancer.

ReNeuron Group (FRA:RQE1) Headlines

No Headlines